Transaction · 0001866174-26-000011

Walsh Colin

WALSH COLIN, DIR, reported an open-market or private sale at Attovia Therapeutics, Inc. involving 76418.000000 shares for an estimated $1607834.72. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code SDIR
ATTOAttovia Therapeutics, Inc.
Trade date
Aug 05, 2026
Filing date
Aug 28, 2026
View on SEC Insider profile
Estimated value-$1.60MShares × reported price
Shares traded76.4k$21.04 per share
Holdings after0Indirect · See Footnotes
% of reported position traded100%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 76,418 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Filing warnings

Notes recorded with this filing
2 warnings
amended filingThis transaction comes from an amended Form 4 filing.
delayed filingThe filing was reported 23 calendar days after the transaction date.

ATTO price since this filing

Daily closing prices, with the filing date and available return windows
ATTO · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001866174-26-000011
Common Stock
Transaction date
Aug 05, 2026
Filed Aug 28, 2026, 09:38 PM · 23d delay
Shares
76,418 sh
$21.04 per share
Estimated value
-$1.60M
Computed from shares × price
Holdings after
0 sh
Indirect · See Footnotes

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Amended Filing Cluster Selling Delayed Filing Large Sale Repeat Seller
Filing-only score

-12 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • amended_filing-6 points

    is_amendment = true

    Amended filing: the original transaction may have been restated.
  • delayed_filing-6 points

    reporting_delay_days = 23

    Filing delay exceeds the configured threshold.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any, and this report shall not be de…

  2. F2

    These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without concedin…

  3. F3

    GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long…

  4. F4

    The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4.…

  5. F5

    Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock on a 9.29-for-1 basis upon the closing of t…

  6. F6

    The Reporting Person is a managing director of GS&Co, a subsidiary of The Goldman Sachs Group Inc. ("GS Group"). GS Group is the direct owner of GS&Co and an indirect owner of Goldman Sachs Asset Mana…

  7. F7

    (continued from footnote 6)... West Street Life Sciences I, L.P. ("WSLS I") which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5…

  8. F8

    (continued from footnote 7)... GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GS…

Amended filing · 0001866174-26-000011
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ATTO